Shots: Dicerna will receive $100M upfront plus ~$350M as development and commercialization milestones with tiered royalties and equity investment of $100M Lilly will get hold of Dicerna’s GalXC RNAi technology as well as development and commercialization rights to new developed drugs in fields of cardio-metabolic diseases, neurodegeneration and pain Dicerna’s GalXC RNAi technology is an […]Read More
Tags : GalXC RNAi technology
Latest Posts
Categories
Related Topics
AbbVie
Acquire
Adults
Agreement
Amgen
approval
AstraZeneca
Bayer
Biosimilar
BMS
Collaborate
Collaborates
Collaboration
Commercialize
COVID-19
Develop
Development
Eli Lilly
EU
Exclusive
FDA
Gilead
GSK
Janssen
Launches
License
License Agreement
Merck
Novartis
P-III
patients
Pfizer
receives
Report
reports
results
Roche
Sanofi
Signs
study
Takeda
the US FDA
Treat
Treatment
US